Myeloid sarcoma of the rib: An atypical isolated chest finding

Raucci, Antonio; Fontanarosa, Antonio; Somma, Pasquale; Bergaminelli, Carlo; Valente, Tullio; Rea, Gaetano

doi:10.1016/j.ejrnm.2014.10.003

Cited by 2 publications

(4 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At least five patients treated for isolated tumor had no clinical response to chemotherapy alone and four died on therapy . Combined local and systemic therapies produced a higher rate of clinical response and 8 of 12 continued disease‐free at 1 to 4 years . Three relapsed and one died after response .…”

Section: Resultsmentioning

confidence: 99%

“…Negative scans were achieved in 38. Of the 35 with available follow‐up, 18 continued disease‐free at 3 months to 6 years (10 over 1 year) . Seven of the patients with negative scans had later scans which documented continued absence of tumor at 7 months to 5 years .…”

Section: Resultsmentioning

confidence: 99%

“…Of the 35 with available follow‐up, 18 continued disease‐free at 3 months to 6 years (10 over 1 year) . Seven of the patients with negative scans had later scans which documented continued absence of tumor at 7 months to 5 years . Of the other 17 cases with negative PET/CT scans, one died after transplant and 16 relapsed within 13 months: 10 in extramedullary sites , 4 in marrow , and 2 in both extramedullary sites and marrow .…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

¹⁸FDG‐PET/CT: 21st century approach to leukemic tumors in 124 cases

Cunningham

Kohno

2016

American J Hematol

View full text Add to dashboard Cite

Extramedullary tumors remain an obstacle to curing more acute leukemia patients. Their incidence is unknown because the presence of occult tumors that contribute to relapse is not routinely sought as in other cancers. No standard approach exists for treating tumors at most sites, apparent clinical response is typically followed by further tumors, and achievement of lengthy remission is uncommon. Body scanning with 18 FDG PET/CT now provides a means to identify the extent of occult tumors that enables directed tumor eradication and a way to evaluate tumor response. To evaluate its potential benefits, analysis was undertaken of 124 published cases scanned after apparent tumors were diagnosed. Clinical and radiologic exams underestimated extent of disease in over half of 100 cases. Among 70 cases that reported scans after various treatments, 70% achieved negative scans. Half relapsed subsequently but disease-free survivals up to 6 years were documented. These reported cases add to our knowledge of extramedullary leukemia in showing that further tumors are more likely than marrow relapse, clinical and radiologic evaluation of response is inadequate, intensive chemotherapy alone generally does not prevent progression and is associated with significant mortality, and tumor-directed plus systemic therapies appears the most effective approach, particularly to AML tumors. This analysis suggests this technology could increase our ability to eradicate all foci of leukemia, and identify tumors responsible for refractory, residual, and relapsed disease.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

¹⁸FDG‐PET/CT: 21st century approach to leukemic tumors in 124 cases

Cunningham

Kohno

2016

American J Hematol

View full text Add to dashboard Cite

show abstract

“…There is no literature data on the effectiveness of the abovementioned treatment regimen, but radiotherapy or surgery used in combination with systemic chemotherapy may be a therapeutic option for MS [14,15].…”

Section: Discussionmentioning

confidence: 99%

Myeloid sarcoma associated with blast crisis in chronic myelogenous leukemia – Case Report

Szymczyk¹,

Podhorecka²,

Tomczak³

et al. 2016

J Pre Clin Clin Res.

View full text Add to dashboard Cite

Introduction. Myeloid sarcoma (MS) is a rare extramedullary tumour which may precede or occur concomitantly with bone marrow involvement in acute myeloid leukemia, myelodysplastic syndrome, or blast crisis in chronic myeloproliferative disorder. Myeloid sarcoma is most commonly found in lymph nodes, skin, subcutaneous tissue and gums, while it is less common in bones, the retroperitoneal space and eye socket. Case Report. The case is reported of a 65-year-old woman with chronic myelogenous leukemia treated for about 20 years with hydroxyurea, 6-mercaptopurine and tyrosine-kinase inhibitors. During the treatment, the general condition of the patient progressively deteriorated, lymphadenopathy and splenomegaly worsened, and blast crisis was diagnosed. After the first cycle of induction chemotherapy, the patient's lymph nodes were swollen and painful. One of the lymph nodes was subjected to histopathology, on the basis of which a diagnosis of MS was made. As the patient showed no response to the treatment, palliative care was initiated. Three months after the diagnosis of MS, the disease progressed. The patient died of infectious complications. Conclusions: A diagnosis of MS, which is considered an adverse prognostic factor, significantly reduces the chances of remission and overall survival in patients with acute myelogenous leukemia or blast crisis inchronic myeloproliferative disorders. It seems that early confirmation of the diagnosis and initiation of the treatment adjusted to the patient's clinical condition may improve the prognosis and increase the response rates.

show abstract

Myeloid sarcoma of the rib: An atypical isolated chest finding

Cited by 2 publications

References 8 publications

¹⁸FDG‐PET/CT: 21st century approach to leukemic tumors in 124 cases

¹⁸FDG‐PET/CT: 21st century approach to leukemic tumors in 124 cases

Myeloid sarcoma associated with blast crisis in chronic myelogenous leukemia – Case Report

Contact Info

Product

Resources

About

Myeloid sarcoma of the rib: An atypical isolated chest finding

Cited by 2 publications

References 8 publications

18FDG‐PET/CT: 21st century approach to leukemic tumors in 124 cases

18FDG‐PET/CT: 21st century approach to leukemic tumors in 124 cases

Myeloid sarcoma associated with blast crisis in chronic myelogenous leukemia – Case Report

Contact Info

Product

Resources

About

¹⁸FDG‐PET/CT: 21st century approach to leukemic tumors in 124 cases

¹⁸FDG‐PET/CT: 21st century approach to leukemic tumors in 124 cases